Abstract | BACKGROUND: METHODS: RESULTS: At baseline, BP did not differ between study arms. After 3 weeks of tolvaptan use, mean body weight had decreased from 79.7 to 78.8 kg, and mean plasma sodium increased from 140.4 to 142.6 mmol/L (both P<0.001), suggesting a decrease in circulating volume. We observed none of these changes in the placebo arm. Nonetheless, BP remained similar in the study arms. After 3 years of treatment, however, mean systolic BP was significantly lower in participants receiving tolvaptan versus placebo (126 versus 129 mm Hg, respectively; P=0.002), as was mean diastolic BP (81.2 versus 82.6 mm Hg, respectively; P=0.01). These differences leveled off at follow-up 3 weeks after discontinuation of the study medication. Use of antihypertensive drugs remained similar in both study arms during the entire study. CONCLUSIONS: CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:
|
Authors | Judith E Heida, Ron T Gansevoort, Vicente E Torres, Olivier Devuyst, Ronald D Perrone, Jennifer Lee, Hui Li, John Ouyang, Arlene B Chapman |
Journal | Journal of the American Society of Nephrology : JASN
(J Am Soc Nephrol)
Vol. 32
Issue 7
Pg. 1801-1812
(Jul 2021)
ISSN: 1533-3450 [Electronic] United States |
PMID | 33888577
(Publication Type: Journal Article)
|
Copyright | Copyright © 2021 by the American Society of Nephrology. |